uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients
Show others and affiliations
2014 (English)In: Expert Opinion on Drug Safety, ISSN 1474-0338, E-ISSN 1744-764X, Vol. 13, no 10, 1305-1317 p.Article, review/survey (Refereed) Published
Abstract [en]

Objective: To identify and characterize drug-induced liver injury (DILI) associated with IFN-beta in multiple sclerosis (MS) using recommended criteria. Methods: This retrospective, mixed methods design included a cohort of IFN-beta exposed MS patients from British Columbia (BC), Canada and a series of DILI cases from other Canadian provinces and two adverse drug reaction (ADR) networks (USA and Sweden). Associations between sex, age and IFN-beta product, and DILI were explored in BC cohort using Cox proportional hazard analyses. Characteristics, including the time to DILI, were compared between sites. Results: In BC, 18/942 (1.9%) of IFN-beta exposed MS patients met criteria for DILI, with a trend toward an increased risk for women and those exposed to IFN-beta-1a SC (44 mcg 3 x weekly) (adjusted Hazard Ratios: 3.15; 95% CI: 0.72 - 13.72, p = 0.13 and 6.26; 95% CI: 0.78 - 50.39, p = 0.08, respectively). Twenty-four additional cases were identified from other sites; the median time to DILI was comparable between BC and other Canadian cases (105 and 90 days, respectively), but longer for the ADR network cases (590 days, p = 0.006). Conclusions: Approximately 1 in 50 IFN-beta exposed patients developed DILI in BC, Canada. Identification of DILI cases from diverse sources highlighted that this reaction occurs even after years of exposure.

Place, publisher, year, edition, pages
2014. Vol. 13, no 10, 1305-1317 p.
Keyword [en]
adverse drug reactions, drug-induced liver injury, IFN-beta, multiple sclerosis
National Category
Pharmacology and Toxicology Pharmaceutical Sciences
URN: urn:nbn:se:uu:diva-235583DOI: 10.1517/14740338.2014.947958ISI: 000342281200004OAI: oai:DiVA.org:uu-235583DiVA: diva2:761474
Available from: 2014-11-06 Created: 2014-11-06 Last updated: 2016-09-30Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Wadelius, Mia
By organisation
Clinical pharmacogenomics and osteoporosis
In the same journal
Expert Opinion on Drug Safety
Pharmacology and ToxicologyPharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 177 hits
ReferencesLink to record
Permanent link

Direct link